About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 72490 record(s)
Req # A-2024-000220
Notice(s) of Violation issued to individual(s) or organization(s) under the Cannabis Act or its Regulations, as referenced on the following webpage: Administrative monetary penalties under the Cannabis Act - Canada.ca.Organization: Health Canada
August 2024
Req # A-2024-000244
All communications to and from Breast Cancer Canada that are held by Health Canada from 2024-03-12 to 2024-05-30.Organization: Health Canada
August 2024
Req # A-2024-000251
The draft product monograph included in the initial filing of the Abbreviated New Drug Submission (ANDS) for Aripiprazole from Jamp Pharma Corporation accepted into review in April 2024 and subsequently, included in the list of Generic submissions…Organization: Health Canada
August 2024
Req # A-2024-000252
The cover letter which accompanied the initial filing of the Abbreviated New Drug Submission (ANDS) for Aripiprazole which was accepted into review in April 2024 and subsequently, included in the list of Generic submissions under review dated 2024-…Organization: Health Canada
August 2024
Req # A-2024-000258
The cover letter which accompanied the initial filing of the Abbreviated New Drug Submission (ANDS) for Tolvaptan which was accepted into review in November 2023 and, is included in the list of Generic submissions under review dated 2024-05-23 and…Organization: Health Canada
August 2024
Req # A-2024-000265
The most recent draft version and any existing feedback pertaining to the performance measurement evaluation for ethylene oxide, mentioned at this Uniform Resource Locator (URL) for greater clarity: https://www.canada.ca/en/health-canada/services/…Organization: Health Canada
August 2024
Req # A-2024-000398
Concerning the Exemptions Division, Office of Controlled Substances / Controlled Substances and Cannabis Branch, Health Canada / Government of Canada: The number of active requests for Section 56 Religious Exemptions currently being processed or…Organization: Health Canada
August 2024
Req # A-2024-000403
The following section of the Electronic Common Technical Document (eCTD) Modules for the CAMBIA® New Drug Submission denoted by Submission Control No. 178225: Section 5.3.1.2.Organization: Health Canada
August 2024
Req # A-2024-000404
The following sections of the Electronic Common Technical Document (eCTD) Modules for CAMBIA® New Drug Submission denoted by Submission Control Number 178225: Section 2.7.1. Section 2.7.6. Section 5.2. Section 5.3.1.1. Section 5.3.1.2. Section 5.3.…Organization: Health Canada
August 2024
Req # A-2024-000405
The following section of the Electronic Common Technical Document (eCTD) Modules for the CAMBIA® New Drug Submissions denoted by Submission Control Nos. 215350 and 253454: Section 5.3.1.2.Organization: Health Canada
August 2024